Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E12.36 EPS (ttm)5.85 Insider Own0.40% Shs Outstand1.31B Perf Week-0.60%
Market Cap94.93B Forward P/E10.88 EPS next Y6.65 Insider Trans-5.70% Shs Float1.29B Perf Month-4.20%
Income7.69B PEG- EPS next Q1.63 Inst Own81.30% Short Float1.03% Perf Quarter-6.84%
Sales23.20B P/S4.09 EPS this Y-22.80% Inst Trans0.17% Short Ratio2.07 Perf Half Y-0.52%
Book/sh16.70 P/B4.33 EPS next Y0.44% ROA3.30% Target Price87.91 Perf Year-10.92%
Cash/sh19.75 P/C3.66 EPS next 5Y-5.41% ROE10.10% 52W Range64.27 - 89.54 Perf YTD0.98%
Dividend2.28 P/FCF17.03 EPS past 5Y36.20% ROI19.90% 52W High-20.48% Beta0.94
Dividend %3.15% Quick Ratio2.90 Sales past 5Y21.90% Gross Margin80.70% 52W Low10.78% ATR1.72
Employees10000 Current Ratio3.00 Sales Q/Q-20.90% Oper. Margin45.40% RSI (14)37.90 Volatility2.73% 2.34%
OptionableYes Debt/Eq1.34 EPS Q/Q-40.80% Profit Margin9.50% Rel Volume0.86 Prev Close72.34
ShortableYes LT Debt/Eq1.20 EarningsOct 25 AMC Payout128.20% Avg Volume6.38M Price71.20
Recom2.10 SMA20-5.77% SMA50-4.79% SMA200-5.29% Volume2,444,580 Change-1.58%
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Sep-05-17Reiterated Wells Fargo Market Perform $73 → $81
Aug-31-17Upgrade Argus Hold → Buy
Oct-23-18 11:09AM  Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook Zacks
07:36AM  The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers Zacks
Oct-22-18 05:36PM  Will Gilead (GILD) HIV Sales Offset HCV Sales Decline in Q3? Zacks
01:17PM  POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET GlobeNewswire
01:15PM  Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet Business Wire
Oct-20-18 06:32PM  PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS TO BE PRESENTED AT 2018 ACR/ARHP ANNUAL MEETING GlobeNewswire
06:30PM  Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting Business Wire
Oct-19-18 05:41PM  Jackpot stocks that could make you a billionaire CNBC Videos
03:15PM  Could a Diagnostic Be Key to Winning This Big Healthcare Market? Motley Fool
08:00AM  Investors Hunt for Biotech Winners as Wider Stock Market Churns Bloomberg
Oct-18-18 09:21PM  Can UnitedHealth Group and Johnson & Johnson Continue Their Winning Ways? Motley Fool
05:45PM  Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know Zacks
01:33PM  Risk-Reward With Gilead Sciences GuruFocus.com
07:00AM  Edited Transcript of GILD earnings conference call or presentation 25-Jul-18 9:00pm GMT Thomson Reuters StreetEvents
07:00AM  Market Morning: China, Yuan Crushed; Fed Minutes Sparse, HIV Meets Match, Exxon Wants China Market Exclusive
06:31AM  Is Sangamo Therapeutics Inc. a Buy? Motley Fool
Oct-16-18 03:01PM  Can This Tiny Biotech Revolutionize a $35 Billion Market? Motley Fool
10:00AM  Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock Motley Fool
Oct-15-18 06:04PM  Trump administration: Drug makers should disclose prices in TV ads Yahoo Finance
08:04AM  2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better Motley Fool
Oct-12-18 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
Oct-11-18 05:34PM  Why a Peninsula cancer fighter soared nearly 40% after record-breaking IPO American City Business Journals
04:05PM  Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018 Business Wire
03:23PM  Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018 Business Wire
Oct-10-18 10:23AM  Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates Zacks
10:18AM  Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status Zacks
Oct-09-18 04:35PM  Better Buy: Crispr Therapeutics AG vs. Editas Motley Fool
11:08AM  Estimating The Intrinsic Value Of Gilead Sciences Inc (NASDAQ:GILD) Simply Wall St.
Oct-05-18 06:14PM  Gilead Sciences (GILD) Stock Moves -0.24%: What You Should Know Zacks
09:55AM  Gilead Announces Positive Data From Ongoing Biktarvy Study Zacks
Oct-04-18 02:24PM  7 Healthcare Stocks to Buy Right Now InvestorPlace
09:19AM  Better Buy: Gilead Sciences, Inc. vs. Pfizer Motley Fool
Oct-03-18 07:33PM  Top 5 Biotech Stocks for 2018 Investopedia
05:30PM  Chartmaster says it's time to fade one of this year's bes... CNBC Videos
04:51PM  Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors Zacks
10:54AM  Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs Zacks
04:55AM  Hong Kong Department of Health Approves Biktarvy(R) (bictegravir, emtricitabine, tenofovir alafenamide) PR Newswire
04:34AM  Hong Kong Department of Health Approves Biktarvy(R) (bictegravir, emtricitabine, tenofovir alafenamide) PR Newswire
Oct-02-18 02:49PM  Cancer Startup's Bold IPO Target Carries 'Management Premium' Bloomberg
01:00PM  Gilead Stock Seen Rising 7% Despite Anemic Growth Investopedia
08:30AM  Kite and HiFiBiO Therapeutics Announce a Research Collaboration to Develop Technology for the Potential Discovery of Neoantigen-Reactive T Cell Receptors (TCRs) for the Treatment of Cancer Business Wire
Oct-01-18 05:30PM  Genentech's first scientist now focused on Bay Area's latest biotech IPO American City Business Journals
11:45AM  5 Reasons to Buy Gilead Stock Today InvestorPlace
10:28AM  5 Best Biotech Stocks to Buy In October Zacks
Sep-28-18 08:16AM  Better Buy: Vertex Pharmaceuticals Incorporated vs. Galapagos NV Motley Fool
Sep-27-18 08:20AM  Analysis: Positioning to Benefit within Enerplus, ExlService, Gilead Sciences, 51job, QUALCOMM, and Perrigo Company plc Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Sep-26-18 08:00PM  Gilead Sciences' Latest Tactic? Go Generic Motley Fool
05:45PM  Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
03:45PM  Gilead Is Undercutting Its Own Drugs: Here's Why Motley Fool
03:21PM  5 Biotech Stocks to Play the Sectors Next Big Trend: NASH InvestorPlace
08:26AM  Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars Zacks
Sep-25-18 04:39PM  Gilead (GILD) to Launch Generics for Leading HCV Treatments Zacks
01:54PM  Gilead Has Strengthened So Go Long and Add to Longs TheStreet.com
Sep-24-18 08:36PM  [$$] Gilead to Slice List Prices of Liver Drugs The Wall Street Journal
04:43PM  CHMP Reconfirms Negative Opinion for Sarepta's Exondys Zacks
04:38PM  [$$] Gilead to Slice List Prices of Liver Drugs The Wall Street Journal
04:32PM  Gilead to launch generic versions of its hepatitis drugs Reuters
04:17PM  Brazil court strips Gilead of hepatitis C drug patent Reuters
04:10PM  Gilead to Sell Cheaper Versions of Drug That Sparked Cost Debate Bloomberg
01:48PM  Brazil court strips Gilead hepatitis drug patent, politician says Reuters
10:19AM  3 Ways to Unpack Some Hidden Treasure in Tesaro Stock InvestorPlace
08:41AM  Rubius (RUBY) in Focus: Stock Moves 8.7% Higher Zacks
08:30AM  Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Business Wire
Sep-23-18 06:33AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Sep-22-18 12:35AM  U.S. Probes Drugmakers Over Free Services The Wall Street Journal
Sep-21-18 06:12PM  FDA Confirms Positive Safety Profile of Acadia's Nuplazid Zacks
03:23PM  U.S. Probes Drugmakers Over Free Services The Wall Street Journal
12:00AM  How Do Drugs Compete Against Each Other? Motley Fool
Sep-20-18 04:23PM  Study shows PrEP effective at stopping HIV infections American City Business Journals
03:53PM  Curing AIDS: After antiretrovirals brought the disease under control, a more ambitious goal is now in sight American City Business Journals
03:49PM  Ultragenyx's Shares Surge More Than 80% in the Year So Far Zacks
11:40AM  Molecular Templates Surges 50%, Inks Cancer Deal With Takeda Zacks
07:32AM  The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences Zacks
Sep-19-18 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
02:07PM  Gilead Faces Doubts on Wall Street a Year After $12 Billion Deal Bloomberg
11:01AM  Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success Zacks
10:13AM  Viking Therapeutics Liver Candidate Passes Test, Shares Soar Zacks
09:30AM  Is Gilead (GILD) a Suitable Stock for Value Investors Now? Zacks
07:45AM  UK rejects adult Novartis CAR-T therapy, after 'yes' in kids Reuters
05:30AM  UK rejects adult Novartis CAR-T therapy, after 'yes' in kids Reuters
05:05AM  UK rejects adult Novartis CAR-T therapy, after 'yes' in kids Reuters
Sep-18-18 06:18PM  Agenus Receives Milestone Payment of $5 Million from Incyte Zacks
03:00PM  Viking Therapeutics and Madrigal Pharmaceuticals Are Racing to the Finish Line in NASH Motley Fool
Sep-17-18 06:13PM  3 High-Quality Biotech Companies for 4th Quarter GuruFocus.com
05:42PM  Health Care Digest: UCSF's ImmunoX revolution, Gilead's deal, a pain breakthrough and more American City Business Journals
02:33PM  Why Gilead Stock Is a Sleepy Giant Waiting to Break Out InvestorPlace
10:03AM  This cancer-fighting biotech sped from startup to IPO filing in 10 months American City Business Journals
09:30AM  Should Value Investors Pick Gilead Sciences (GILD) Stock? Zacks
Sep-14-18 09:53AM  Unity (UBX) Catches Eye: Stock Jumps 8.8% Zacks
07:00AM  Gilead taps Durham gene editing firm for $445M deal American City Business Journals
06:15AM  A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis Motley Fool
Sep-13-18 03:48PM  How Gilead Call Prices Tripled Overnight TheStreet.com
03:07PM  Gilead taps Durham gene editing firm for $445M deal American City Business Journals
11:18AM  Gilead Inks Gene Editing Collaboration Deal for HBV Infection Zacks
10:34AM  Company News For Sep 13, 2018 Zacks
08:53AM  Better Buy: Gilead Sciences, Inc. vs. Biogen Motley Fool
06:31AM  What's Next for Gilead Sciences After Its Latest Clinical Success Motley Fool
Sep-12-18 03:40PM  Gilead's Rheumatoid Arthritis Drug Successful in Phase III Zacks
12:46PM  Here's Why Galapagos NV Is Skyrocketing 18.3% Today Motley Fool
11:31AM  Stocks - Apple Gains in Pre-market; Facebook, Google Fall; Nielsen Jumps Investing.com
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CDirectorOct 01Option Exercise23.6050,0001,180,0003,067,762Oct 03 05:45 PM
MARTIN JOHN CDirectorOct 01Sale78.0450,0003,902,2103,017,762Oct 03 05:45 PM
MARTIN JOHN CDirectorSep 04Option Exercise23.6050,0001,180,0003,067,762Sep 06 05:24 PM
MARTIN JOHN CDirectorSep 04Sale74.1650,0003,708,0343,017,762Sep 06 05:24 PM
MARTIN JOHN CDirectorAug 01Option Exercise23.6050,0001,180,0003,067,762Aug 03 04:41 PM
MARTIN JOHN CDirectorAug 01Sale77.8550,0003,892,6503,017,762Aug 03 04:41 PM
MARTIN JOHN CDirectorJul 02Option Exercise23.6050,0001,180,0003,067,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJul 02Sale70.8150,0003,540,2823,017,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJun 01Option Exercise23.6050,0001,180,0003,067,762Jun 05 07:34 PM
MARTIN JOHN CDirectorJun 01Sale68.1350,0003,406,4953,017,762Jun 05 07:34 PM
MILLIGAN JOHN FPresident and CEOMay 04Option Exercise27.0780,0002,165,6001,294,306May 08 06:29 PM
Cogan John FrancisDirectorMay 04Option Exercise26.625,836155,32558,455May 08 01:59 PM
Cogan John FrancisDirectorMay 04Sale65.095,836379,88552,619May 08 01:59 PM
MARTIN JOHN CDirectorMay 01Option Exercise23.6050,0001,180,0003,067,762May 03 01:07 PM
MARTIN JOHN CDirectorMay 01Sale72.1950,0003,609,6603,017,762May 03 01:07 PM
Cogan John FrancisDirectorApr 27Option Exercise26.625,833155,24558,452Apr 30 05:39 PM
Cogan John FrancisDirectorApr 27Sale73.915,833431,11752,619Apr 30 05:39 PM
Cogan John FrancisDirectorApr 20Option Exercise26.625,833155,24558,452Apr 23 07:16 PM
Cogan John FrancisDirectorApr 20Sale73.745,833430,13052,619Apr 23 07:16 PM
Cogan John FrancisDirectorApr 13Option Exercise26.625,833155,24558,452Apr 16 06:45 PM
Cogan John FrancisDirectorApr 13Sale75.565,833440,74152,619Apr 16 06:45 PM
Cogan John FrancisDirectorApr 06Option Exercise26.625,833155,24558,452Apr 09 06:41 PM
Cogan John FrancisDirectorApr 06Sale74.475,833434,38452,619Apr 09 06:41 PM
MARTIN JOHN CDirectorApr 02Option Exercise23.6050,0001,180,0003,067,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Option Exercise26.625,833155,24558,452Apr 04 04:23 PM
MARTIN JOHN CDirectorApr 02Sale73.1450,0003,656,8063,017,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Sale74.935,833437,06752,619Apr 04 04:23 PM
Cogan John FrancisDirectorMar 23Option Exercise26.625,833155,24558,452Mar 26 06:48 PM
Cogan John FrancisDirectorMar 23Sale75.025,833437,58852,619Mar 26 06:48 PM
Cogan John FrancisDirectorMar 16Option Exercise26.625,833155,24558,452Mar 20 01:28 PM
Cogan John FrancisDirectorMar 16Sale80.095,833467,13852,619Mar 20 01:28 PM
Cogan John FrancisDirectorMar 12Option Exercise26.625,833155,24558,452Mar 13 04:29 PM
Cogan John FrancisDirectorMar 12Sale80.935,833472,06552,619Mar 13 04:29 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise23.6050,0001,180,0003,067,762Mar 05 06:54 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00178012,233Mar 05 08:42 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Option Exercise40.5617,250699,66069,426Mar 05 07:04 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Sale78.6925,0001,967,31544,426Mar 05 07:04 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale78.6550,0003,932,3753,017,762Mar 05 06:54 PM
Washington Robin LEVP, CFOFeb 28Sale80.315,000401,566105,405Mar 02 06:47 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 20Sale81.5414,4351,176,9920Feb 21 06:51 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.00908016,237Feb 13 04:58 PM
WILSON GAYLE EDirectorFeb 09Option Exercise26.6260,0001,596,900182,258Feb 13 05:24 PM
WILSON GAYLE EDirectorFeb 09Sale77.9260,0004,675,080122,258Feb 13 05:24 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Option Exercise40.5617,250699,66062,738Feb 05 09:20 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.00620015,547Feb 02 09:14 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise23.6050,0001,180,0003,046,766Feb 05 08:38 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Sale83.5125,0002,087,86037,738Feb 05 09:20 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale83.5650,0004,177,8242,996,766Feb 05 08:38 PM
Meyers James REVP Worldwide Commercial OpsJan 16Option Exercise21.58100,0002,157,500102,715Jan 18 06:31 PM
Meyers James REVP Worldwide Commercial OpsJan 16Sale80.24100,0008,024,3642,715Jan 18 06:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Option Exercise36.0225,875932,06275,488Jan 16 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Sale79.0030,0002,370,00045,488Jan 16 05:42 PM
MARTIN JOHN CExecutive ChairmanJan 02Option Exercise23.6050,0001,180,0003,046,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Option Exercise24.918,625214,80664,613Jan 04 08:05 PM
MARTIN JOHN CExecutive ChairmanJan 02Sale73.6250,0003,681,2352,996,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Sale73.8715,0001,108,01949,613Jan 04 08:05 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise21.5873,3331,582,1593,070,099Dec 05 07:49 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Option Exercise24.918,625214,80670,988Dec 05 06:17 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale74.9873,3335,498,3852,996,766Dec 05 07:49 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Sale74.6415,0001,119,55255,988Dec 05 06:17 PM
MILLIGAN JOHN FPresident and CEONov 13Option Exercise21.58220,0004,746,5001,385,924Nov 15 03:19 PM
MILLIGAN JOHN FPresident and CEONov 13Sale72.88220,00016,034,6781,165,924Nov 15 03:19 PM
Meyers James REVP Worldwide Commercial OpsNov 05Option Exercise0.004,50007,215Nov 07 05:47 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Option Exercise24.918,625214,80677,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise21.5873,3331,582,1593,070,099Nov 03 07:04 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Sale74.8215,0001,122,28562,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale75.1373,3335,509,6972,996,766Nov 03 07:04 PM